查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1858087

止吐藥市場按適應症、藥物類別、給藥途徑、最終用戶和分銷管道分類－2025-2032年全球預測

Antiemetic Drugs Market by Indication, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，止吐藥市場規模將達到 117.8 億美元，複合年成長率為 8.97%。

關鍵市場統計數據
基準年 2024 59.2億美元
預計年份：2025年 64.4億美元
預測年份 2032 117.8億美元
複合年成長率 (%) 8.97%

介紹止吐藥物，重點闡述其臨床重要性、不斷變化的患者需求以及創新與支持性護理的交匯點。

止吐藥物處於臨床治療、病患體驗和商業策略的交會點。在現代腫瘤學、手術全期護理和放射治療中，人們不僅關注臨床療效，也重視藥物的耐受性和生活品質，這使得止吐藥物在治療路徑中的作用從輔助手段提升至核心地位。因此，臨床醫生、支付方和醫療服務提供者正在從更廣泛的角度評估止吐藥物的選擇，包括給藥的便利性、安全性以及與多模式支持治療方案的整合。

此外，醫療服務模式的變革，例如門診化療、居家輸液服務和日間手術中心的擴展，正在改變人們對給藥途徑和產品包裝的期望。患者和臨床醫生都在尋求可靠的口服藥物，既能保持療效，又能確保患者在院外也能堅持用藥；而醫療系統則優先考慮能夠減少患者再次入院率並提高醫療服務效率的干涉措施。因此，製造商和經銷商必須調整其商業模式，以適應不斷變化的採購流程和臨床醫生的工作流程。

最後，監管細則的澄清和指南的更新正在加強循證處方，而報銷和合約環境也持續影響處方決策。總而言之，這些因素既給開發商、醫療服務提供者和醫療系統帶來了挑戰，也帶來了機遇，幫助他們改善支持性照護效果和營運效率。

止吐療法的變革性轉變：藥物創新、數位化醫療整合與治療模式變革

止吐藥物領域正經歷巨大的變革時期，這主要得益於藥理學、製劑和治療模式的進步。近年來，更多標靶性藥物和組合方案的研發，在提高止吐療效的同時，顯著降低了副作用。這些藥理學創新與改進的製劑相輔相成，提高了口服生物有效性並延長了治療持續時間。因此，臨床醫生現在可以根據治療強度、患者合併症和實際操作限制，選擇更合適的治療方案。

同時，醫療模式正朝著以病人為中心的方向轉變。遠端醫療追蹤、遠距症狀監測和數位化依從性工具正被擴大用於了解患者在實際環境中的耐受性，並指導支持性干預措施。這些數位化輔助工具能夠更早發現突破性噁心，並及時升級或調整止吐治療方案，從而改善治療效果，減輕急診服務的負擔。同時，供應鏈韌性和策略採購正成為製造商和醫療系統的優先事項，促使他們投資於本地製造能力和多元化的供應商網路。

此外，總醫療成本指標和病患報告結局已成為支付方和醫院籌資策略的核心。這種轉變有利於減少後續資源利用的干涉措施，例如減少非計劃門診就診和延長住院時間，從而提升那些能夠顯著改善耐受性和依從性的止吐藥的商業價值。總而言之，這些轉變正在重塑臨床實踐和競爭格局，要求相關人員調整其研發、市場准入和商業化策略。

評估2025年美國關稅對止吐藥供應鏈、定價權、策略採購及生產韌性的累積影響

2025年的關稅情勢預示著包括止吐藥在內的各類藥品供應鏈最佳化和商業規劃將面臨新的挑戰。進口關稅和貿易政策的調整加劇了對全球籌資策略的審查，迫使製造商重新評估活性藥物原料藥、輔料和成品的生產地點。為此，多家公司加快了緊急時應對計畫的實施，以減少對單一國家供應節點的依賴，並降低價格和前置作業時間的波動風險。

因此，採購團隊和委託製造製造商已將供應商多元化和雙重採購安排列為優先事項，以確保供應的連續性。這些措施包括對區域製造外包進行資格認證、增加關鍵零件的庫存緩衝以及重新談判長期合約以納入關稅應急條款。同時，監管和品質監督仍然是重中之重。本地化工作必須符合嚴格的製造標準，同時最大限度地減少對現有監管備案和分銷協議的影響。

從策略角度來看，企業正在採取多種風險緩解策略，包括將部分生產環節轉移到近岸地區、投資供應鏈可視性工具以及與分銷合作夥伴緊密合作以最佳化市場通路物流。同時，支付方和醫療系統越來越重視可預測的供應和穩定的價格，並將此作為納入藥品目錄和優先簽約的標準。總而言之，2025年累積關稅的影響將強化企業採取具有韌性、透明且區域平衡的生產和籌資策略的獎勵。

將適應症、藥物類別、給藥途徑、終端用戶行為和分銷管道聯繫起來，形成可操作的細分洞察，從而指導策略制定。

市場細分為將臨床需求轉化為產品、市場准入和商業策略提供了一個實用的架構。基於適應症的市場動態因化療引起的噁心嘔吐、術後噁心嘔吐和放療引起的噁心嘔吐而異，每種適應症都有其獨特的療效、用藥時機和安全性要求。化療相關方案通常需要多藥預防和可預測的藥物動力學，而術後用藥則強調起效迅速和適合短期住院，放療相關的噁心可能需要延長給藥時間並採用分次給藥方案。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大專為兒科和老年患者設計的口服Ondansetron製劑的市場
  • 提高藥物基因體學資料的整合度，以實現癌症患者止吐治療的個人化。
  • 為對抗化療引起的噁心，神經激肽-1受體拮抗劑的研究正在加速推進。
  • 生技公司與學名藥生產商進行策略合作，共同開發具成本效益的止吐藥物
  • 數位化用藥依從性工具和行動應用程式的快速湧現，有助於提高止吐治療方案的依從性。
  • 對標靶中樞催吐通路肽類止吐候選藥物的投資不斷成長
  • COVID-19 供應鏈中斷對新興市場注射止吐藥供應的影響

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依適應症分類的止吐藥市場

  • 化療引起的噁心和嘔吐
  • 術後噁心嘔吐
  • 放射線引起的噁心和嘔吐

9. 按藥物類別分類的止吐藥市場

  • 皮質類固醇
  • 多巴胺拮抗劑
  • 神經激肽1受體拮抗劑
  • 血清素5-HT3受體拮抗劑

第10章 依給藥途徑分類的止吐藥市場

  • 靜脈
  • 口服

第11章 依最終用戶分類的止吐藥市場

  • 診所
  • 居家照護
  • 醫院

第12章：止吐藥市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：各地區止吐藥市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 止吐藥市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國止吐藥市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Merck & Co., Inc.
    • Helsinn Healthcare SA
    • Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Mylan NV
    • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-C002B1C996F2

The Antiemetic Drugs Market is projected to grow by USD 11.78 billion at a CAGR of 8.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.92 billion
Estimated Year [2025] USD 6.44 billion
Forecast Year [2032] USD 11.78 billion
CAGR (%) 8.97%

Introduces antiemetic therapeutics, highlighting clinical importance, evolving patient needs, and the intersection of innovation and supportive care

Antiemetic therapeutics sit at the intersection of clinical care, patient experience, and commercial strategy. Modern oncology, perioperative medicine, and radiation therapy increasingly emphasize not only clinical efficacy but also tolerability and quality of life, elevating the role of antiemetics from supportive adjuncts to core components of treatment pathways. As a result, clinicians, payers, and providers now evaluate antiemetic choices through a broader lens that includes administration convenience, safety profiles, and integration with multimodal supportive care protocols.

Moreover, shifts in care delivery-most notably the expansion of outpatient chemotherapy, home-based infusion services, and ambulatory surgery centers-have altered expectations for route of administration and product packaging. Patients and clinicians demand reliable oral options that preserve efficacy while enabling adherence outside the hospital, and health systems prioritize interventions that reduce readmissions and improve throughput. Consequently, manufacturers and distributors must adapt commercial models to align with evolving procurement processes and clinician workflows.

Finally, regulatory clarity and guideline updates have reinforced evidence-driven prescribing, while reimbursement and contracting environments continue to shape formulary decisions. Taken together, these forces create both constraints and opportunities for developers, suppliers, and health systems seeking to improve supportive care outcomes and operational efficiency.

Transformative shifts in antiemetic therapy driven by pharmacologic innovation, digital care integration, and changing delivery models

The antiemetic landscape is undergoing substantive transformation driven by advances in pharmacology, formulation science, and care delivery models. Recent years have produced more targeted agents and combination regimens that enhance emetic control while reducing adverse effects, and these pharmacologic innovations are complemented by formulation improvements that expand oral bioavailability and prolong therapeutic windows. As a result, clinicians can select regimens that better match treatment intensity, patient comorbidities, and logistical constraints.

Concurrently, care models are shifting toward patient-centric approaches. Telehealth-enabled follow-up, remote symptom monitoring, and digital adherence tools are increasingly used to capture real-world tolerability and to guide supportive interventions. These digital adjuncts allow for earlier identification of breakthrough nausea and enable timely escalation or modification of antiemetic therapy, improving outcomes and reducing the burden on acute care services. Parallel to this, supply chain resilience and strategic sourcing have risen as priorities for manufacturers and health systems, prompting investment in regional manufacturing capacity and diversified supplier networks.

In addition, payer and hospital procurement strategies now center on total cost of care metrics and patient-reported outcomes. This change favors interventions that reduce downstream resource utilization, such as unscheduled clinic visits and prolonged hospital stays, thereby elevating the commercial value of antiemetics that demonstrably improve tolerability and adherence. Collectively, these shifts are reshaping clinical practice and the competitive landscape, requiring stakeholders to realign R&D, market access, and commercialization strategies.

Assessing the cumulative impact of United States tariffs in 2025 on antiemetic supply chains, pricing dynamics, strategic sourcing, and manufacturing resilience

The tariff landscape introduced in 2025 ushered in a new set of variables for supply chain optimization and commercial planning across pharmaceutical categories, including antiemetics. Import duties and trade policy adjustments have increased scrutiny of global sourcing strategies, prompting manufacturers to re-evaluate where active pharmaceutical ingredients, excipients, and finished-dose manufacturing occur. In response, several firms accelerated contingency planning to reduce dependence on single-country supply nodes and to mitigate price and lead-time volatility.

Consequently, procurement teams and contract manufacturers have prioritized supplier diversification and dual-sourcing arrangements to preserve continuity of supply. These actions include qualification of regional contract manufacturing organizations, increased inventory buffering for critical components, and renegotiation of long-term contracts to incorporate tariff contingency clauses. At the same time, regulatory and quality oversight remain central; localization efforts must satisfy stringent manufacturing standards while minimizing disruptions to existing regulatory filings and distribution agreements.

From a strategic perspective, companies have adopted multiple risk-mitigation tactics that include nearshoring select production steps, investing in supply visibility tools, and coordinating closely with distribution partners to optimize route-to-market logistics. Payers and health systems, for their part, are increasingly focused on predictable supply and stable pricing as criteria for formulary placement and preferred contracting. In sum, the cumulative tariff impacts of 2025 have strengthened incentives for resilient, transparent, and regionally balanced manufacturing and procurement strategies.

Actionable segmentation insights connecting indication, drug class, administration route, end user behavior, and distribution channel guidance for strategy

Segmentation provides a practical framework to translate clinical needs into product, access, and commercial strategies. Based on Indication, market dynamics differ across chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and radiation-induced nausea and vomiting, each presenting unique efficacy, timing, and safety imperatives. Chemotherapy-associated protocols often require multi-agent prophylaxis and predictable pharmacokinetics; post-operative use emphasizes rapid onset and suitability for short-stay settings; radiation-related nausea may demand extended-duration control for fractionated regimens.

Based on Drug Class, decision criteria and formulary placement pivot on attributes of corticosteroids, dopamine antagonists, neurokinin 1 receptor antagonists, and serotonin 5-HT3 receptor antagonists, with each class offering distinct benefit-risk trade-offs that influence regimen selection and combination approaches. Corticosteroids provide broad antiemetic augmentation but carry systemic effects that must be managed. Dopamine antagonists supply alternative mechanisms but demand attention to neurologic tolerability. Neurokinin 1 receptor antagonists and serotonin 5-HT3 receptor antagonists remain foundational for guideline-driven prophylaxis, and evolving formulations aim to optimize adherence and convenience.

Based on Route Of Administration, outcomes and channel strategies diverge between intravenous and oral options, shaping procurement preferences in hospitals and outpatient settings and influencing product development priorities. Based on End User, clinics, home care settings, and hospitals each impose different stocking practices, dispensing workflows, and clinician touchpoints that affect uptake and adherence. Based on Distribution Channel, hospital pharmacy, online pharmacy, and retail pharmacy routes carry distinct reimbursement pathways, inventory models, and patient access considerations that determine where and how products gain traction. By integrating these segmentation lenses, stakeholders can align clinical evidence generation, commercial messaging, and distribution tactics to the real-world requirements of each use case.

Regional insights on how Americas, Europe, Middle East & Africa, and Asia-Pacific dynamics influence access, reimbursement, distribution, and clinical adoption

Regional dynamics materially influence every aspect of antiemetic development, approval, distribution, and adoption. In the Americas, diverse payer landscapes and a mix of public and private procurement systems create incentives for evidence demonstrating reductions in downstream healthcare utilization; consequently, formulary positioning often hinges on total cost of care narratives and supply reliability. In North America, outpatient oncology and ambulatory surgery growth have elevated demand for convenient oral options and compact packaging suited to home administration.

In Europe, Middle East & Africa, regulatory harmonization across jurisdictions and national procurement processes shape entry strategies, with reimbursement timelines and health technology assessment outcomes guiding commercialization sequencing. Local manufacturing and distribution partnerships frequently reduce lead times and support compliance with regional procurement rules, and in some countries system-level purchasing emphasizes affordable, generic-friendly options.

In Asia-Pacific, rapid expansion of oncology services, increased uptake of outpatient care models, and heterogeneous regulatory pathways present both opportunity and complexity. Investment in regional manufacturing infrastructure and strategic partnerships can accelerate access, while tailored clinical evidence that reflects local treatment paradigms supports uptake. Across all regions, distribution channel evolution and digital health adoption vary markedly, and stakeholders must calibrate pricing, stakeholder engagement, and supply strategies to local drivers to secure sustainable access and clinical integration.

Key company insights examining competitive positioning, R&D priorities, strategic partnerships, manufacturing footprint, and commercialization strategies

Competitive dynamics in the antiemetic space reflect a blend of established therapeutic classes, generics competition, and incremental innovation through new formulations and combination regimens. Companies that sustain differentiated value propositions-whether through long-acting formulations, fixed-dose combinations, or convenience-focused packaging-tend to secure preferential procurement and clinician loyalty. Strategic partnerships across development, manufacturing, and distribution channels further accelerate market entry and reduce execution risk.

R&D priorities now emphasize not only mechanistic efficacy but also tolerability, dosing convenience, and evidence of downstream healthcare savings. This shift has stimulated cross-functional collaborations between clinical teams and real-world evidence groups to capture patient-reported outcomes and healthcare utilization endpoints. In addition, manufacturing footprint and supply chain transparency have become competitive differentiators; companies that can demonstrate robust, diversified supply and quick replenishment capabilities gain favor with large hospital systems and integrated delivery networks.

Commercial models increasingly blend direct-to-provider engagement, digital tools to support patient adherence, and targeted contracting with payers and group purchasing organizations. Firms that articulate clear value across clinical, operational, and economic dimensions, and that can adapt to regional procurement nuances, will be better positioned to convert clinical advantage into sustainable commercial performance.

Actionable recommendations to strengthen supply resilience, accelerate adoption, optimize distribution, and prioritize patient-centric innovation

Leaders should prioritize a short set of high-impact actions to preserve access, support clinicians, and capture commercial value. First, reinforce supply chain resilience through supplier diversification, strategic regional partnerships, and inventory visibility tools that enable rapid response to disruption. Second, accelerate development of patient-centric formulations and packaging that support outpatient and home-care administration, thereby aligning product attributes with evolving care pathways.

Third, invest in evidence generation that demonstrates not only symptom control but also reductions in downstream resource use and improvements in patient-reported outcomes; such evidence strengthens negotiations with payers and hospital procurement teams. Fourth, deploy digital adherence and remote monitoring solutions to support real-world use, reduce breakthrough events, and collect post-launch data that inform iterative product positioning. Fifth, refine commercial approaches to suit distribution channels-hospital pharmacy, online pharmacy, and retail pharmacy-ensuring that reimbursement, logistics, and clinician engagement align with channel-specific expectations.

Finally, integrate tariff and trade policy risk into strategic planning by considering nearshoring, contractual tariff protections, and scenario-based financial modeling. By sequencing these actions with clear owners and measurable KPIs, organizations can move from reactive to proactive management of clinical, operational, and commercial risks.

Robust research methodology combining primary expert engagement, structured secondary review, data triangulation, validation, and limitation disclosure

The analysis underpinning this report integrates structured primary and secondary research practices to ensure methodological rigor and practical relevance. Primary inputs include interviews with clinical experts, procurement leaders, and commercial executives to capture experiential insights on prescribing behavior, purchasing priorities, and supply chain constraints. Secondary review comprises peer-reviewed literature, clinical guideline analyses, regulatory documentation, and publicly available policy statements to contextualize clinical and policy drivers.

Data triangulation is applied across sources to validate thematic findings and to reconcile divergent perspectives. Quality controls included standardized interview guides, independent coding of qualitative inputs, and cross-verification of critical claims with multiple expert respondents. Limitations are acknowledged, including potential variability in regional practice patterns and the evolving nature of policy interventions. These limitations are disclosed transparently, and findings are presented with caveats where applicable to support informed decision-making.

Concise conclusion synthesizing strategic imperatives, priorities, and considerations to guide stakeholders through antiemetic challenges and opportunities

The antiemetic therapeutic area presents a convergence of clinical need, delivery model change, and commercial complexity that demands strategic clarity. Stakeholders who align product attributes with evolving care settings-particularly outpatient and home-based administration-while reinforcing supply resilience will be better positioned to meet clinician and payer expectations. Meanwhile, evidence generation that quantifies patient-centered benefits and operational savings remains a powerful lever for formulary inclusion and contracting.

Looking ahead, organizations should balance near-term operational actions with longer-term investments in formulation innovation and digital support tools. By doing so, they can reduce acute care utilization, improve patient adherence, and create defensible differentiation against generic competition. Ultimately, the most successful stakeholders will be those that integrate clinical insight, supply chain agility, and pragmatic commercialization into a cohesive strategy that responds to both immediate pressures and enduring patient needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expanding market for oral dissolvable ondansetron formulations tailored to pediatric and geriatric patients
  • 5.2. Increasing integration of pharmacogenomics data to personalize antiemetic therapy in oncology patients
  • 5.3. Surge in research on neurokinin-1 receptor antagonists addressing breakthrough chemotherapy-induced nausea
  • 5.4. Strategic partnerships between biotech firms and generics manufacturers to co-develop cost effective antiemetic solutions
  • 5.5. Rapid emergence of digital adherence tools and mobile apps enhancing patient compliance with antiemetic regimens
  • 5.6. Growing investment in peptide based antiemetic candidates targeting central vomiting pathways
  • 5.7. Impact of COVID-19 supply chain disruptions on availability of injectable antiemetic drugs in emerging markets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antiemetic Drugs Market, by Indication

  • 8.1. Chemotherapy-Induced Nausea And Vomiting
  • 8.2. Post-Operative Nausea And Vomiting
  • 8.3. Radiation-Induced Nausea And Vomiting

9. Antiemetic Drugs Market, by Drug Class

  • 9.1. Corticosteroids
  • 9.2. Dopamine Antagonists
  • 9.3. Neurokinin 1 Receptor Antagonists
  • 9.4. Serotonin 5-HT3 Receptor Antagonists

10. Antiemetic Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Antiemetic Drugs Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care Settings
  • 11.3. Hospitals

12. Antiemetic Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Antiemetic Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antiemetic Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antiemetic Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Merck & Co., Inc.
    • 16.3.2. Helsinn Healthcare SA
    • 16.3.3. Hoffmann-La Roche AG
    • 16.3.4. GlaxoSmithKline plc
    • 16.3.5. Novartis AG
    • 16.3.6. Teva Pharmaceutical Industries Ltd.
    • 16.3.7. Pfizer Inc.
    • 16.3.8. Dr. Reddy's Laboratories Ltd.
    • 16.3.9. Mylan N.V.
    • 16.3.10. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTIEMETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTIEMETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIEMETIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 122. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 134. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 136. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 170. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 182. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 183. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 184. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 185. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 208. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 209. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 210. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 211. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. GCC ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GCC ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GCC ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 220. GCC ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 221. GCC ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 222. GCC ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 223. GCC ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 224. GCC ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 225. GCC ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. GCC ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. GCC ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. GCC ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 244. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 245. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 246. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 247. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. G7 ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. G7 ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. G7 ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 256. G7 ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 257. G7 ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. G7 ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. G7 ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. G7 ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. G7 ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. G7 ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. G7 ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. G7 ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. NATO ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. NATO ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. NATO ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. NATO ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 269. NATO ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. NATO ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. NATO ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. NATO ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. NATO ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. NATO ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. NATO ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. NATO ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 281. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 283. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 290. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 291. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 300. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 301. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 302. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 303. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 304. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 305. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 309. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 310. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 311. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 312. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 313. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 314. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 315. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 320. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 321. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 322. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 323. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 324. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 329. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 330. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 331. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 332. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 333. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 334. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 335. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 336. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 337. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 338. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 339. FRANCE ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 340. FRANCE